Russell Investments Group, Ltd. Bei Gene, Ltd. Transaction History

Russell Investments Group, Ltd.

  • $66.8 Billion
  • Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 13,856 shares of BGNE stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,856
Previous 21 65880.95%
Holding current value
$2.68 Million
Previous $2,000 155400.0%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$143.93 - $224.51 $1.99 Million - $3.11 Million
13,835 Added 65880.95%
13,856 $3.11 Million
Q2 2024

Aug 08, 2024
BUY
$129.52 - $174.32 $2,719 - $3,660
21 New
21 $2,000
Q4 2023

Feb 05, 2024
SELL
$158.67 - $201.58 $66,324 - $84,260
-418 Reduced 5.91%
6,650 $1.2 Million
Q3 2023

Nov 13, 2023
SELL
$179.87 - $225.13 $1.71 Million - $2.14 Million
-9,502 Reduced 57.34%
7,068 $1.27 Million
Q2 2023

Aug 10, 2023
SELL
$178.3 - $266.78 $1.42 Million - $2.13 Million
-7,974 Reduced 32.49%
16,570 $2.95 Million
Q1 2023

May 09, 2023
BUY
$215.53 - $274.5 $3.97 Million - $5.06 Million
18,429 Added 301.37%
24,544 $5.29 Million
Q4 2022

Feb 08, 2023
BUY
$125.51 - $229.3 $463,884 - $847,492
3,696 Added 152.79%
6,115 $1.34 Million
Q3 2022

Nov 04, 2022
SELL
$131.8 - $202.24 $144,980 - $222,464
-1,100 Reduced 31.26%
2,419 $326,000
Q2 2022

Jul 29, 2022
SELL
$121.11 - $216.05 $323,363 - $576,853
-2,670 Reduced 43.14%
3,519 $569,000
Q1 2022

May 05, 2022
SELL
$146.52 - $269.56 $75,604 - $139,092
-516 Reduced 7.7%
6,189 $1.17 Million
Q4 2021

Jan 21, 2022
SELL
$248.56 - $389.34 $157,338 - $246,452
-633 Reduced 8.63%
6,705 $1.82 Million
Q3 2021

Nov 08, 2021
BUY
$249.6 - $403.14 $1.15 Million - $1.86 Million
4,622 Added 170.18%
7,338 $2.66 Million
Q2 2021

Aug 04, 2021
SELL
$292.75 - $367.01 $375,305 - $470,506
-1,282 Reduced 32.07%
2,716 $932,000
Q1 2021

May 10, 2021
BUY
$260.64 - $382.12 $19,808 - $29,041
76 Added 1.94%
3,998 $1.39 Million
Q4 2020

Feb 08, 2021
BUY
$221.31 - $316.61 $624,979 - $894,106
2,824 Added 257.19%
3,922 $1 Million
Q3 2020

Nov 09, 2020
SELL
$189.18 - $286.44 $10.7 Million - $16.2 Million
-56,528 Reduced 98.09%
1,098 $311,000
Q2 2020

Aug 05, 2020
SELL
$123.9 - $195.41 $8.12 Million - $12.8 Million
-65,526 Reduced 53.21%
57,626 $10.9 Million
Q1 2020

May 06, 2020
SELL
$121.84 - $173.19 $5.14 Million - $7.31 Million
-42,194 Reduced 25.52%
123,152 $15.2 Million
Q4 2019

Jan 29, 2020
SELL
$115.78 - $208.34 $1.14 Million - $2.05 Million
-9,850 Reduced 5.62%
165,346 $27.4 Million
Q3 2019

Nov 01, 2019
SELL
$120.61 - $148.29 $13 Million - $16 Million
-107,561 Reduced 38.04%
175,196 $21.5 Million
Q2 2019

Aug 09, 2019
SELL
$113.99 - $146.86 $13.2 Million - $17 Million
-115,787 Reduced 29.05%
282,757 $35.1 Million
Q1 2019

May 13, 2019
BUY
$122.82 - $151.83 $14 Million - $17.3 Million
113,796 Added 39.96%
398,544 $52.5 Million
Q4 2018

Feb 11, 2019
BUY
$107.01 - $175.15 $19.2 Million - $31.3 Million
178,984 Added 169.23%
284,748 $39.9 Million
Q3 2018

Oct 26, 2018
BUY
$152.62 - $189.66 $2 Million - $2.48 Million
13,077 Added 14.11%
105,764 $18.2 Million
Q2 2018

Aug 08, 2018
SELL
$152.5 - $216.77 $1.38 Million - $1.95 Million
-9,018 Reduced 8.87%
92,687 $14.2 Million
Q1 2018

May 11, 2018
BUY
$97.41 - $177.22 $6.1 Million - $11.1 Million
62,597 Added 160.06%
101,705 $17.1 Million
Q4 2017

Feb 06, 2018
BUY
$79.6 - $114.73 $3.11 Million - $4.49 Million
39,108
39,108 $3.83 Million

Others Institutions Holding BGNE

# of Institutions
244
Shares Held
45.3M
Call Options Held
258K
Put Options Held
52.2K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email